COYA vs. NVCT, CTMX, OPTN, ADAG, CTXR, CRVO, NGM, RLMD, BRNS, and VTGN
Should you be buying Coya Therapeutics stock or one of its competitors? The main competitors of Coya Therapeutics include Nuvectis Pharma (NVCT), CytomX Therapeutics (CTMX), OptiNose (OPTN), Adagene (ADAG), Citius Pharmaceuticals (CTXR), CervoMed (CRVO), NGM Biopharmaceuticals (NGM), Relmada Therapeutics (RLMD), Barinthus Biotherapeutics (BRNS), and Vistagen Therapeutics (VTGN). These companies are all part of the "pharmaceutical preparations" industry.
Coya Therapeutics (NASDAQ:COYA) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings.
Nuvectis Pharma received 1 more outperform votes than Coya Therapeutics when rated by MarketBeat users. Likewise, 87.50% of users gave Nuvectis Pharma an outperform vote while only 85.71% of users gave Coya Therapeutics an outperform vote.
Coya Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500.
Coya Therapeutics currently has a consensus target price of $14.00, indicating a potential upside of 67.26%. Nuvectis Pharma has a consensus target price of $21.00, indicating a potential upside of 227.61%. Given Nuvectis Pharma's higher probable upside, analysts clearly believe Nuvectis Pharma is more favorable than Coya Therapeutics.
39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 9.8% of Coya Therapeutics shares are held by company insiders. Comparatively, 38.9% of Nuvectis Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Nuvectis Pharma had 2 more articles in the media than Coya Therapeutics. MarketBeat recorded 7 mentions for Nuvectis Pharma and 5 mentions for Coya Therapeutics. Nuvectis Pharma's average media sentiment score of 1.33 beat Coya Therapeutics' score of 0.56 indicating that Nuvectis Pharma is being referred to more favorably in the news media.
Coya Therapeutics has higher revenue and earnings than Nuvectis Pharma. Coya Therapeutics is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.
Coya Therapeutics' return on equity of -42.53% beat Nuvectis Pharma's return on equity.
Summary
Nuvectis Pharma beats Coya Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Coya Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Coya Therapeutics Competitors List
Related Companies and Tools
